The Medicines Regulator of Britain has urged that the AstraZeneca vaccine for the corona virus continue to be taken, although seven people in the UK have been revealed to have died of rare blood clots after receiving the vaccine.

The British Agency said that it was not clear whether the doses caused clots, and that "a thorough review of UK reports on rare and specific types of blood clots continues."

Overall, the agency said it had identified 30 cases of rare blood clots out of 18.1 million doses of AstraZeneca that had been given as of March 24. The risk associated with this type of blood clot was "very low."

Dr. John Rain, CEO of the Agency, said: "The benefits of the AstraZeneca vaccine in preventing COFID-19 infection and its complications continue to outweigh any risks, and the public must continue to obtain the vaccine when invited to do so."

Concerns about the AstraZeneca vaccine have led some countries, including Canada, France, Germany and the Netherlands, to limit its use to older persons.

Britain, which has introduced corona vaccines faster than other European countries, relies in particular on the AstraZeneca vaccine, developed by scientists at the University of Oxford.

There were no reports of any blood clots around the Pfizer-Biontic vaccine, which had also been widely released in the United Kingdom.